Munich, Germany, Jan. 20, 2026 (GLOBE NEWSWIRE) — smartbax, a biotech company developing next-generation antibiotics against multi-drug resistant bacteria, today announced the in-licensing of a new compound class from the antibacterial portfolio of Aicuris Anti-infective Cures AG to expand its proprietary pipeline of small-molecule antibiotics. The small molecule disrupts bacterial cell wall synthesis by blocking […]

New York, Jan. 20, 2026 (GLOBE NEWSWIRE) — Crisis Text Line, a leading nonprofit organization that provides free, 24/7, confidential mental health support, today released The Hidden Economic Value of Online Crisis Volunteers, a new global study led by the organization that quantifies the economic footprint of trained volunteer online crisis counselors operating at scale

Preclinical in vivo efficacy data in atopic dermatitis extend previous PoC in allergic asthma Positive opinion from the European Patent Office strengthens patent protection of ATP-R13 Progress significantly enhances the strategic attractiveness of ATP-R13 as a broadly applicable, disease-modifying therapy across multiple allergic indications Geneva (Switzerland), January 20, 2026 – Atopia Therapeutics, a leader in

SANDWICH, United Kingdom, Jan. 20, 2026 (GLOBE NEWSWIRE) — Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), today announces the US Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for LEVI-04. This enables the initiation of further clinical development as a

— Women’s Health Receives Only 6% of Private Healthcare Investment, Despite Women Accounting for Nearly Half the World’s Population, According to the World Economic Forum’s 2026 Women’s Health Investment Outlook, Published in Collaboration with BCG — The Limited Available Funds Mainly Flow into Women’s Cancers, Reproductive Health, and Maternal Health, While Other High-Burden, High-Prevalence Conditions

Zadarma, a global VoIP service provider, announces the launch of the Zadarma AI Voice Agent. This virtual assistant handles calls, uses a natural, realistic voice, and communicates with customers during and outside business hours. The AI voice agent uses your existing knowledge base to provide customers with accurate information. It can also transfer calls to

GIBO Holdings Ltd. (NASDAQ: GIBO), Asia’s leading innovation-driven AI ecosystem, today announced the next evolution of its AI mobility roadmap, advancing the GIBO.ai Calculation Engine toward a unified, cross-domain intelligence stack supporting progressively autonomous air and ground mobility systems. Following strong industry and partner feedback on its AI-powered aerial intelligence services, GIBO is now extending

Thoughtworks’ agentic development platform developed to support both technology modernization and greenfield development. Thoughtworks, a global technology consultancy that integrates design, engineering and AI to drive digital innovation, today announced the launch of AI/works(TM), a new agentic development platform that sets the standard for modernizing legacy systems and building new industrial-grade technology products and platforms

In head-to-head non-human primate (NHP) studies, average observed half-life of ASC37 was approximately 17 days, 7-fold longer than retatrutide, which supports once-monthly subcutaneous (SQ) dosing in humans. ASC37's average in vitro activity was approximately 5-, 4-, and 4-fold more potent than retatrutide for GLP-1R, GIPR and GCGR, respectively. Submission of an Investigational New Drug Application

smartbax in-licenses lead antibacterial compound targeting Gram-negative infections from Aicuris GlobeNewswire January 20, 2026 Munich, Germany, Jan. 20, 2026 (GLOBE NEWSWIRE) — smartbax, a biotech company developing next-generation antibiotics against multi-drug resistant bacteria, today announced the in-licensing of a new compound class from the antibacterial portfolio of Aicuris Anti-infective Cures AG to expand its proprietary